Document is current
Any future updates will be listed below
-
Authors
Liu, Lihong
Iketani, Sho
Guo, Yicheng http://orcid.org/0000-0001-5357-660X
Chan, Jasper F.-W. http://orcid.org/0000-0001-6336-6657
Wang, Maple
Liu, Liyuan
Luo, Yang http://orcid.org/0000-0003-3277-8792
Chu, Hin http://orcid.org/0000-0003-2855-9837
Huang, Yiming
Nair, Manoj S. http://orcid.org/0000-0002-5994-3957
Yu, Jian
Chik, Kenn K.-H.
Yuen, Terrence T.-T.
Yoon, Chaemin
To, Kelvin K.-W. http://orcid.org/0000-0002-1921-5824
Chen, Honglin http://orcid.org/0000-0001-5108-8338
Yin, Michael T.
Sobieszczyk, Magdalena E.
Huang, Yaoxing http://orcid.org/0000-0001-6270-1644
Wang, Harris H. http://orcid.org/0000-0003-2164-4318
Sheng, Zizhang
Yuen, Kwok-Yung http://orcid.org/0000-0002-2083-1552
Ho, David D. http://orcid.org/0000-0003-1627-149X
- License Information
-
More Information
Article History
Received: 14 December 2021
Accepted: 23 December 2021
First Online: 23 December 2021
Competing interests
: Lihong Liu, S.I., M.S.N., J.Y., Yaoxing Huang and D.D.H. are inventors on patent applications (WO2021236998) or provisional patent applications (63/271,627) filed by Columbia University for a number of SARS-CoV-2 neutralizing antibodies described in this manuscript. Both sets of applications are under review. D.D.H. is a co-founder of TaiMed Biologics and RenBio, consultant to WuXi Biologics and Brii Biosciences, and board director for Vicarious Surgical.
Free to read: This content has been made available to all.
